TVGN at a glance
Tevogen Bio Holdings Inc. (TVGN, SEC CIK 1860871) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on August 14, 2026, an 8-K current report on September 30, 2026 and Form 4 insider filings as recently as September 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of December 31, 2025, 18 institutional investment managers tracked by SignalX reported holding Tevogen Bio Holdings Inc. (TVGN) shares worth $1.2 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 18 funds
- $1.2M · +3 vs prior quarter
- Latest 8-K
- Sep 30, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no product revenue generated to date
- Net loss $5.8M vs $5.5M YoY; operating loss $5.7M vs $5.4M
- R&D expenses $3.3M vs $2.7M; G&A expenses $2.4M vs $2.7M
- Cash $1.1M at June 30; $3.0M PIPE completed May 15
- Sufficient funding for at least 12 months; R&D expenses expected to increase significantly over several years
Risk Factors
- Newly added Nasdaq listing risk triggered by April 2026 deficiency notices for $50 million MVLS and $15 million MVPHS requirements
- Most material update: Nasdaq compliance deadlines of October 13, 2026 and October 14, 2026
- Regulatory risk: failure to regain compliance could delist common stock and public warrants from Nasdaq
- Market risk: delisting could reduce security liquidity and impair investors’ ability to trade
- Financial risk: no material changes disclosed from the Annual Report’s liquidity, debt, or currency risks
AI summary of the TVGN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.1: Item EX-99.1
- Nasdaq Global Market compliance restored under the $50 million minimum market value requirement
- Minimum market value of publicly held shares requirement also satisfied
Item 8.01: Other Events
- Tevogen regained compliance with Nasdaq’s $50 million minimum market value requirement under Rule 5450(b)(2)(A)
- Continued listing on The Nasdaq Global Market preserved, reducing delisting risk for TVGN and TVGNW holders
Item 5.02: Departure/Appointment of Directors or Principal Officers
- CEO Ryan Saadi granted 8,000,000 restricted shares; CFO Kirti Desai granted 750,000 under the 2024 incentive plan
- Vesting requires $1.0 billion aggregate revenue by September 30, 2031, tying compensation to a major long-term growth milestone
Item 8.01: Other Events
- Nasdaq confirmed Tevogen regained compliance with the $15 million minimum market value requirement
- Continued listing on The Nasdaq Global Market preserved for TVGN and TVGNW
AI summaries of TVGN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for TVGN
Don't miss the next TVGN filing
- Alerts as it files. A push when TVGN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut TVGN, by share count.
- Ask anything. An AI agent that reads every TVGN filing and answers with sources.
TVGN alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Saadi Ryan H. | A | Sep 14, 2026 | 8,000,000 | - |
| Desai Kirti | A | Sep 14, 2026 | 750,000 | - |
| Patton Curtis L. | A | Sep 11, 2026 | 75,000 | - |
| Feike Jeffrey L. | A | Sep 11, 2026 | 75,000 | - |
| Sordillo Victor J. | A | Sep 11, 2026 | 75,000 | - |
| PODLOGAR SUSAN M | A | Sep 11, 2026 | 75,000 | - |
| Goh Keow Lin | A | Sep 11, 2026 | 75,000 | - |
| Saadi Ryan H. | A | Jul 10, 2026 | 1,220,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$8.8M | -$53.6M | -$26.1M |
| Net Income | -$67K | -$13.7M | -$26.3M |
| Balance Sheet | |||
| Total Assets | $17.0M | $3.5M | $4.4M |
| Equity | -$17.4M | -$6.7M | -$8.2M |
| ROE | 0.4% | 205.7% | 319.1% |
| Per Share | |||
| EPS | $-2.44 | $-0.07 | $-8.08 |
| Cash Flow | |||
| Operating CF | -$1.4M | -$12.0M | -$12.3M |
| CapEx | $133K | - | $64K |
Source: XBRL data in Tevogen Bio Holdings Inc. (TVGN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q4 2025Aggregate TVGN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q4 2025 | 18 | $1.2M |
| Q3 2025 | 15 | $2.7M |
| Q2 2025 | 15 | $4.3M |
| Q1 2025 | 12 | $1.8M |
| Q4 2024 | 8 | $547,000 |
| Q3 2024 | 5 | $80,000 |
- Goldman Sachs Group+152.6K (+126%)
- Morgan Stanley+123.6K (+98%)
- Vanguard Group Inc+44.7K (+4%)
- Wells Fargo & Co+25.1K (+124%)
- State Street Corp+17.7K (+15%)
- BlackRock−357.4K (-23%)
- BNY Mellon−23.6K (-42%)
- JPMorgan Chase & Co−12.6K (-25%)
- AQR Capital Management−9.8K (-43%)
- Invesco Ltd−6.3K (-35%)
- Citadel Advisors LLC+17.2K
- Prudential Financial+11.5K
- StoneX Group Inc.+10.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 73 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
TVGN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 30, 2026 | - | Analysis | - |
| 4 | Sep 16, 2026 | - | - | - |
| 4 | Sep 16, 2026 | - | - | - |
| 8-K | Sep 16, 2026 | - | Analysis | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 8-K | Sep 10, 2026 | - | Analysis | - |
| 8-K | Aug 26, 2026 | - | Analysis | - |
| 10-Q | Aug 14, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 4 | Jul 10, 2026 | - | - | - |
| 4 | Jul 10, 2026 | - | - | - |
| 4 | Jul 10, 2026 | - | - | - |
| 4 | Jul 10, 2026 | - | - | - |
| 4 | Jul 10, 2026 | - | - | - |
| 4 | Jul 10, 2026 | - | - | - |
| 4 | Jul 10, 2026 | - | - | - |
| 10-Q | May 15, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 22, 2026 | - | Analysis | - |
| 10-K | Mar 31, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 25, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
TVGN SEC filings: frequently asked questions
Which institutions hold TVGN stock?
As of December 31, 2025, the largest Tevogen Bio Holdings Inc. (TVGN) holders among the 13F filers tracked by SignalX were BlackRock ($395,000), Vanguard Group Inc ($376,000), Goldman Sachs Group ($91,000), Morgan Stanley ($83,000), Northern Trust ($65,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What did TVGN report in its latest 8-K?
Tevogen Bio Holdings Inc. (TVGN) filed an 8-K on September 30, 2026 reporting Item 8.01 (Other Events). Nasdaq Global Market compliance restored under the $50 million minimum market value requirement.
What are the latest TVGN SEC filings?
Tevogen Bio Holdings Inc. (TVGN) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on August 14, 2026, an 8-K current report on September 30, 2026 and a Form 4 insider filing on September 16, 2026.
What is TVGN's SEC CIK number?
Tevogen Bio Holdings Inc. (TVGN)'s SEC Central Index Key (CIK) is 1860871. EDGAR lists every TVGN filing under that number.
Ask anything about TVGN
The research agent reads TVGN's filings, financials, insider trades and 13F holders, then answers with sources.